NEW YORK and SALT LAKE CITY - Citeline announced an expanded partnership with Recursion (NASDAQ:RXRX) on Tuesday to integrate real-world data capabilities into the biotech company’s drug development ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In March 2026, Citeline announced an expanded strategic partnership with Recursion Pharmaceuticals to integrate Citeline's real-world data and evidence into Recursion’s tech-enabled drug discovery and ...
We recently published 10 Big Names With Explosive Growth. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals jumped by 16.44 percent on ...
Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...
Director Christopher Gibson of Recursion Pharmaceuticals NASDAQ:RXRX, sold 40,000 shares of Class A Common Stock at a price of $3.25 on March 23, 2026, for a total of $130,000.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results